This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - exenatide

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

NICE guidance states that a GLP-1 mimetic (incretin mimetic) (exenatide) is a therapeutic option in type 2 diabetes.

In the latest guidance (2) NICE state that:

If triple therapy (metformin tolerant treatment arm) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, an SU and a GLP-1 mimeticc for adults with type 2 diabetes who:

  • have a BMI of 35 kg/m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or
  • have a BMI lower than 35 kg/m2, and for whom insulin therapy would have significant occupational implications, or weight loss would benefit other significant obesity-related comorbidities

Continuation of GLP-1

  • Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol/mol [1.0%] in HbA1c and a weight loss of at least 3% of initial body weight in 6 months)

For detailed guidance then consult the full guideline (2).

Reference:

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.